Nephrology

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

The adjusted change in 24-hour systolic blood pressure was -11.0 mm Hg in the chlorthalidone group and -0.5 mm Hg in the placebo group.

Though immunogenicity responses to the vaccine were lower in dialysis patients, the lower response rate was less apparent in second doses.

Patients with Crohn's disease often also suffer from kidney dysfunction.

The new PDUFA date for Nefecon will be December 15, 2021.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

Investigators urge patients undergoing hemodialysis to adhere to their COVID-19 vaccination schedules, as data show a low antibody response.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

The new SLE test enhances specificity without sacrificing sensitivity.

The FDA noted the extent of the treatment effect of tenapanor is of unclear clinical significance, despite evidence of efficacy.

The priorities established by a panel of experts are designed to improve efficacy and equity in kidney research and care.

The treatment met all 5 primary efficacy endpoints as part of the ASCEND program.

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

Patients with chronic kidney disease reported poor quality of life, particularly in domains related to their condition.

Older age, macroalbuminaria, and high diastolic blood pressure are among some of the risk factors significantly associated with onset of chronic kidney disease.

Baseline eGFR and increasing age were good predictors of eGFR.

There was a notable association between the comorbid population and congestive heart failure exacerbations.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

The single 1000 mg dose treats iron deficiency anemia in adult patients.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.